Amphiphilic Cationic Nanogels as Brain-Targeted Carriers for Activated Nucleoside Reverse Transcriptase Inhibitors

G. Warren, E. Makarov, Y. Lu, T. Senanayake, K. Rivera, S. Gorantla, L. Y. Poluektova, S. V. Vinogradov

Research output: Contribution to journalArticle

7 Citations (Scopus)

Abstract

Progress in AIDS treatment shifted emphasis towards limiting adverse effects of antiviral drugs while improving the treatment of hard-to-reach viral reservoirs. Many therapeutic nucleoside reverse transcriptase inhibitors (NRTI) have a limited access to the central nervous system (CNS). Increased NRTI levels induced various complications during the therapy, including neurotoxicity, due to the NRTI toxicity to mitochondria. Here, we describe an innovative design of biodegradable cationic cholesterol-ε-polylysine nanogel carriers for delivery of triphosphorylated NRTIs that demonstrated high anti-HIV activity along with low neurotoxicity, warranting minimal side effects following systemic administration. Efficient CNS targeting was achieved by nanogel modification with brain-specific peptide vectors. Novel dual and triple-drug nanoformulations, analogous to therapeutic NRTI cocktails, displayed equal or higher antiviral activity in HIV-infected macrophages compared to free drugs. Our results suggest potential alternative approach to HIV-1 treatment focused on the effective nanodrug delivery to viral reservoirs in the CNS and reduced neurotoxicity.

Original languageEnglish (US)
Pages (from-to)88-101
Number of pages14
JournalJournal of Neuroimmune Pharmacology
Volume10
Issue number1
DOIs
StatePublished - Feb 20 2015

Fingerprint

Reverse Transcriptase Inhibitors
Nucleosides
Central Nervous System
Brain
Antiviral Agents
HIV
Polylysine
Pharmaceutical Preparations
HIV-1
Mitochondria
Acquired Immunodeficiency Syndrome
Therapeutics
Macrophages
Cholesterol
Peptides
NanoGel

Keywords

  • Abacavir
  • Blood–brain barrier
  • Brain-specific peptides
  • Central nervous system
  • HIV-1
  • Lamivudine
  • NRTI 5′-triphosphates
  • Nanogels
  • Neurotoxicity
  • Nucleoside reverse transcriptase inhibitors
  • Zidovudine
  • ε-polylysine

ASJC Scopus subject areas

  • Neuroscience (miscellaneous)
  • Immunology and Allergy
  • Immunology
  • Pharmacology

Cite this

Amphiphilic Cationic Nanogels as Brain-Targeted Carriers for Activated Nucleoside Reverse Transcriptase Inhibitors. / Warren, G.; Makarov, E.; Lu, Y.; Senanayake, T.; Rivera, K.; Gorantla, S.; Poluektova, L. Y.; Vinogradov, S. V.

In: Journal of Neuroimmune Pharmacology, Vol. 10, No. 1, 20.02.2015, p. 88-101.

Research output: Contribution to journalArticle

Warren, G. ; Makarov, E. ; Lu, Y. ; Senanayake, T. ; Rivera, K. ; Gorantla, S. ; Poluektova, L. Y. ; Vinogradov, S. V. / Amphiphilic Cationic Nanogels as Brain-Targeted Carriers for Activated Nucleoside Reverse Transcriptase Inhibitors. In: Journal of Neuroimmune Pharmacology. 2015 ; Vol. 10, No. 1. pp. 88-101.
@article{8c592629685744debe05ad850baf3be1,
title = "Amphiphilic Cationic Nanogels as Brain-Targeted Carriers for Activated Nucleoside Reverse Transcriptase Inhibitors",
abstract = "Progress in AIDS treatment shifted emphasis towards limiting adverse effects of antiviral drugs while improving the treatment of hard-to-reach viral reservoirs. Many therapeutic nucleoside reverse transcriptase inhibitors (NRTI) have a limited access to the central nervous system (CNS). Increased NRTI levels induced various complications during the therapy, including neurotoxicity, due to the NRTI toxicity to mitochondria. Here, we describe an innovative design of biodegradable cationic cholesterol-ε-polylysine nanogel carriers for delivery of triphosphorylated NRTIs that demonstrated high anti-HIV activity along with low neurotoxicity, warranting minimal side effects following systemic administration. Efficient CNS targeting was achieved by nanogel modification with brain-specific peptide vectors. Novel dual and triple-drug nanoformulations, analogous to therapeutic NRTI cocktails, displayed equal or higher antiviral activity in HIV-infected macrophages compared to free drugs. Our results suggest potential alternative approach to HIV-1 treatment focused on the effective nanodrug delivery to viral reservoirs in the CNS and reduced neurotoxicity.",
keywords = "Abacavir, Blood–brain barrier, Brain-specific peptides, Central nervous system, HIV-1, Lamivudine, NRTI 5′-triphosphates, Nanogels, Neurotoxicity, Nucleoside reverse transcriptase inhibitors, Zidovudine, ε-polylysine",
author = "G. Warren and E. Makarov and Y. Lu and T. Senanayake and K. Rivera and S. Gorantla and Poluektova, {L. Y.} and Vinogradov, {S. V.}",
year = "2015",
month = "2",
day = "20",
doi = "10.1007/s11481-014-9576-7",
language = "English (US)",
volume = "10",
pages = "88--101",
journal = "Journal of NeuroImmune Pharmacology",
issn = "1557-1890",
publisher = "Springer New York",
number = "1",

}

TY - JOUR

T1 - Amphiphilic Cationic Nanogels as Brain-Targeted Carriers for Activated Nucleoside Reverse Transcriptase Inhibitors

AU - Warren, G.

AU - Makarov, E.

AU - Lu, Y.

AU - Senanayake, T.

AU - Rivera, K.

AU - Gorantla, S.

AU - Poluektova, L. Y.

AU - Vinogradov, S. V.

PY - 2015/2/20

Y1 - 2015/2/20

N2 - Progress in AIDS treatment shifted emphasis towards limiting adverse effects of antiviral drugs while improving the treatment of hard-to-reach viral reservoirs. Many therapeutic nucleoside reverse transcriptase inhibitors (NRTI) have a limited access to the central nervous system (CNS). Increased NRTI levels induced various complications during the therapy, including neurotoxicity, due to the NRTI toxicity to mitochondria. Here, we describe an innovative design of biodegradable cationic cholesterol-ε-polylysine nanogel carriers for delivery of triphosphorylated NRTIs that demonstrated high anti-HIV activity along with low neurotoxicity, warranting minimal side effects following systemic administration. Efficient CNS targeting was achieved by nanogel modification with brain-specific peptide vectors. Novel dual and triple-drug nanoformulations, analogous to therapeutic NRTI cocktails, displayed equal or higher antiviral activity in HIV-infected macrophages compared to free drugs. Our results suggest potential alternative approach to HIV-1 treatment focused on the effective nanodrug delivery to viral reservoirs in the CNS and reduced neurotoxicity.

AB - Progress in AIDS treatment shifted emphasis towards limiting adverse effects of antiviral drugs while improving the treatment of hard-to-reach viral reservoirs. Many therapeutic nucleoside reverse transcriptase inhibitors (NRTI) have a limited access to the central nervous system (CNS). Increased NRTI levels induced various complications during the therapy, including neurotoxicity, due to the NRTI toxicity to mitochondria. Here, we describe an innovative design of biodegradable cationic cholesterol-ε-polylysine nanogel carriers for delivery of triphosphorylated NRTIs that demonstrated high anti-HIV activity along with low neurotoxicity, warranting minimal side effects following systemic administration. Efficient CNS targeting was achieved by nanogel modification with brain-specific peptide vectors. Novel dual and triple-drug nanoformulations, analogous to therapeutic NRTI cocktails, displayed equal or higher antiviral activity in HIV-infected macrophages compared to free drugs. Our results suggest potential alternative approach to HIV-1 treatment focused on the effective nanodrug delivery to viral reservoirs in the CNS and reduced neurotoxicity.

KW - Abacavir

KW - Blood–brain barrier

KW - Brain-specific peptides

KW - Central nervous system

KW - HIV-1

KW - Lamivudine

KW - NRTI 5′-triphosphates

KW - Nanogels

KW - Neurotoxicity

KW - Nucleoside reverse transcriptase inhibitors

KW - Zidovudine

KW - ε-polylysine

UR - http://www.scopus.com/inward/record.url?scp=84925488612&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84925488612&partnerID=8YFLogxK

U2 - 10.1007/s11481-014-9576-7

DO - 10.1007/s11481-014-9576-7

M3 - Article

C2 - 25559020

AN - SCOPUS:84925488612

VL - 10

SP - 88

EP - 101

JO - Journal of NeuroImmune Pharmacology

JF - Journal of NeuroImmune Pharmacology

SN - 1557-1890

IS - 1

ER -